BioCentury | Jan 24, 2011
Company News

Emerging Healthcare Solutions Inc. hepatic, gene/cell therapy news

...cells in simulated weightlessness. Emerging Healthcare Solutions has rights to the technology in China from Regenetech Inc....
BioCentury | Jan 3, 2011
Company News

Emerging Healthcare Solutions Inc., Regenetech deal

...Emerging Healthcare Solutions received a sublicense from Regenetech to use NASA's Intrifuge Rotary Cell Culture System...
...treat liver disease. Further terms were not disclosed. Emerging Healthcare Solutions Inc. (Pink:EHSI), Houston, Texas Regenetech Inc....
BioCentury | Nov 19, 2007
Company News

Regenetech, Johns Hopkins University deal

...The university will use Regenetech's Intrifuge Bioreactor to develop a treatment for Type I diabetes using...
...to develop a treatment for Type I diabetes using a patient's own adult stem cells. Regenetech...
...the two-year deal and have an option to resulting IP. Financial terms were not disclosed. Regenetech Inc....
BioCentury | Nov 12, 2007
Company News

Regenetech, Regenevita S.A. de C.V. deal

...Regenevita received exclusive rights to commercialize Regenetech's cellXpansion technology in Mexico. Regenevita will use the technology...
...cells from blood, which it will sell for R&D uses. Financial terms were not disclosed. Regenetech Inc....
Items per page:
1 - 4 of 4
BioCentury | Jan 24, 2011
Company News

Emerging Healthcare Solutions Inc. hepatic, gene/cell therapy news

...cells in simulated weightlessness. Emerging Healthcare Solutions has rights to the technology in China from Regenetech Inc....
BioCentury | Jan 3, 2011
Company News

Emerging Healthcare Solutions Inc., Regenetech deal

...Emerging Healthcare Solutions received a sublicense from Regenetech to use NASA's Intrifuge Rotary Cell Culture System...
...treat liver disease. Further terms were not disclosed. Emerging Healthcare Solutions Inc. (Pink:EHSI), Houston, Texas Regenetech Inc....
BioCentury | Nov 19, 2007
Company News

Regenetech, Johns Hopkins University deal

...The university will use Regenetech's Intrifuge Bioreactor to develop a treatment for Type I diabetes using...
...to develop a treatment for Type I diabetes using a patient's own adult stem cells. Regenetech...
...the two-year deal and have an option to resulting IP. Financial terms were not disclosed. Regenetech Inc....
BioCentury | Nov 12, 2007
Company News

Regenetech, Regenevita S.A. de C.V. deal

...Regenevita received exclusive rights to commercialize Regenetech's cellXpansion technology in Mexico. Regenevita will use the technology...
...cells from blood, which it will sell for R&D uses. Financial terms were not disclosed. Regenetech Inc....
Items per page:
1 - 4 of 4